This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While these powerful weight loss drugs are effective, a significant portion of the lost weight is lean body mass, raising concerns about potential long-term effects on physical function and health. Several investigational drugs, including SARMs and antimostatin agents, are in clinical trials to determine if they can preserve or build muscle mass and enhance fat loss when used in combination with GLP-1s. Experts emphasize the need for trials to demonstrate improved function and confirm the safety of these new agents, as some have been linked to potential adverse events.
Audio Overview (Google NotebookLM)
(12 minutes 10 seconds)
